Erratum: Discovery of tetrahydropyrazolopyrimidine carboxamide derivatives as potent and orally active novel antitubercular agents (ACS Medicinal Chemistry Letters (2013) 4:5 (451-455) DOI: 10.1021/ml400071a);Discovery of tetrahydropyrazolopyrimidine carboxamide derivatives as potent and orally active antitubercular agents

ACS Medicinal Chemistry Letters

Volumn 4, Issue 5, 2013, Pages 451-455

  Yokokawa, Fumiaki ^a   Wang, Gang ^a   Chan, Wai Ling ^a   Ang, Shi Hua ^a   Wong, Josephine ^a   Ma, Ida ^a   Rao, Srinivasa P S ^a   Manjunatha, Ujjini ^a   Lakshminarayana, Suresh B ^a   Herve, Maxime ^a   Kounde, Cyrille ^a   Tan, Bee Huat ^a   Thayalan, Pamela ^a   Ng, Seow Hwee ^a   Nanjundappa, Mahesh ^a   Ravindran, Sindhu ^a   Gee, Peck ^a   Tan, Maria ^a   Wei, Liu ^a   Goh, Anne ^a   Chen, Pei Yu ^a   Lee, Kok Sin ^a   Zhong, Chen ^b   Wagner, Trixie ^c   Dix, Ina ^c   Chatterjee, Arnab K ^b,d   Pethe, Kevin ^b,e   Kuhen, Kelli ^b   Glynne, Richard ^b   Smith, Paul ^a   Bifani, Pablo ^a   Jiricek, Jan ^a   more..

^a NOVARTIS INSTITUTE FOR TROPICAL DISEASES   (Singapore)

^b GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d California Institute for Biomedical Research   (United States)

^e Institute Pasteur Korea   (South Korea)

Author keywords

Antituberculosis; structure activity relationship; structure property relationship; tetrahydropyrazolo 1,5 a pyrimidine

Indexed keywords

ETHAMBUTOL; TETRAHYDROPYRAZOLOPYRIMIDINE CARBOXAMIDE DERIVATIVE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ARTICLE; COLONY FORMING UNIT; DRUG EFFICACY; DRUG POTENCY; DRUG RESISTANT TUBERCULOSIS; DRUG SYNTHESIS; HIGH THROUGHPUT SCREENING; IN VIVO STUDY; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE PROPERTY RELATION; STRUCTURE ACTIVITY RELATION; WHOLE CELL;

EID: 84877697081     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml500020r     Document Type: Erratum

References (13)

1. World Health Organization. Multidrug and Extensively Drug-Resistant TB: 2010 Global Report on Surveillance and Response.
2. Ma, Z.; Lienhardt, C.; McIlleron, H.; Nunn, A. J.; Wang, X. Global tuberculosis drug development pipeline: the need and the reality Lancet 2010, 375, 2100-2109
3. Koul, A.; Arnoult, E.; Lounis, N.; Guillemont, J.; Andries, K. The challenge of new drug discovery for tuberculosis Nature 2011, 469, 483-490
4. Pethe, K.; Sequeira, P. C.; Agarwalla, S.; Rhee, K.; Kuhen, K.; Phong, W. Y.; Patel, V.; Beer, D.; Walker, J. R.; Duraiswamy, J.; Jiricek, J.; Keller, T. H.; Chatterjee, A.; Tan, M. P.; Ujjini, M.; Rao, S. P.; Camacho, L.; Bifani, P.; Mak, P. A.; Ma, I.; Barnes, S. W.; Chen, Z.; Plouffe, D.; Thayalan, P.; Ng, S. H.; Au, M.; Lee, B. H.; Tan, B. H.; Ravindran, S.; Nanjundappa, M.; Lin, X.; Goh, A.; Lakshminarayana, S. B.; Shoen, C.; Cynamon, M.; Kreiswirth, B.; Dartois, V.; Peters, E. C.; Glynne, R.; Brenner, S.; Dick, T. A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy Nat. Commun. 2010, 1, 57
5. Maddry, J. A.; Ananthan, S.; Goldman, R. C.; Hobrath, J. V.; Kwong, C. D.; Maddox, C.; Rasmussen, L.; Reynolds, R. C.; Secrist, J. A., III; Sosa, M. I.; White, E. L.; Zhang, W. Antituberculosis activity of the molecular libraries screening center network library Tuberculosis 2009, 89, 354-363
6. Ballel, L.; Bates, R. H.; Young, R. J.; Alvarez-Gomez, D.; Alvarez-Ruiz, E.; Barroso, V.; Blanco, D.; Crespo, B.; Escribano, J.; Gonzalez, R.; Lozano, S.; Huss, S.; Santos-Villarejo, A.; Martin-Plaza, J. J.; Mendoza, A.; Rebollo-Lopez, M. J.; Remuinan-Blanco, M.; Lavandera, J. L.; Perez-Herran, E.; Gamo-Benito, F. J.; Garcia-Bustos, J. F.; Barros, D.; Castro, J. P.; Cammack, N. Fueling Open-Source Drug Discovery: 177 Small-Molecule Leads against Tuberculosis ChemMedChem 2013, 8, 313-321
7. Alvarez-Ruiz, E.; Ballell-Pages, L.; Castro-Pichel, J.; Encinas, L.; Esquivias, J.; Gamo-Benito, F. J.; Garcia-Palancar, M. C.; Remuinan-Blanco, M. J. Tetrahydropyrazolo [1,5- a ] Pyrimidine As Anti-Tuberculosis Compounds. Patent WO2012/143522.
8. Dalinger, I. L.; Vatsadse, I. A.; Shevelev, S. A.; Ivachtchenko, A. V. Liquid-phase synthesis of combinatorial libraries based on 7-trifluoromethyl- substituted pyrazolo [1,5-a] pyrimidine scaffold J. Comb. Chem. 2005, 7, 236-245
9. Yoshida, M.; Mori, A.; Inaba, A.; Oka, M.; Makino, H.; Yamaguchi, M.; Fujita, H.; Kawamoto, T.; Goto, M.; Kimura, H.; Baba, A.; Yasuma, T. Synthesis and structure-activity relationship of tetrahydropyrazolopyrimidine derivatives: A novel structural class of potent calcium-sensing receptor antagonists Bioorg. Med. Chem. 2010, 18, 8501-8511
10. Yoshida, M.; Mori, A.; Kotani, E.; Oka, M.; Makino, H.; Fujita, H.; Ban, J.; Ikeda, Y.; Kawamoto, T.; Goto, M.; Kimura, H.; Baba, A.; Yasuma, T. Discovery of novel and potent orally active calcium-sensing receptor antagonists that stimulate pulselike parathyroid hormone secretion: Synthesis and structure-activity relationships of tetrahydropyrazolopyrimidine derivatives J. Med. Chem. 2011, 54, 1430-1440
11. Yoshida, M.; Mori, A.; Morimoto, S.; Kotani, E.; Oka, M.; Notoya, K.; Makino, H.; Ono, M.; Shirasaki, M.; Tada, N.; Fujita, H.; Ban, J.; Ikeda, Y.; Kawamoto, T.; Goto, M.; Kimura, H.; Baba, A.; Yasuma, T. Novel and potent calcium-sensing receptor antagonists: Discovery of (5 R)- N -[1-ethyl-1-(4- ethylphenyl)propyl]-2,7,7-trimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo [1,5-a] pyrimidine-3-carboxamide monotosylate (TAK-075) as an orally active bone anabolic agent Bioorg. Med. Chem. 2011, 19, 1881-1894
12. Klingensmith, L. M.; Strieter, E. R.; Barder, T. E.; Buchwald, S. L. New insights into Xantphos/Pd-Catalyzed C-N bond forming reactions: A structural and kinetic study Organometallics 2006, 25, 82-91
13. Bifani, P.; Lakshminarayana, S.; Rao, S.; Ma, I.; Tan, B. H.; Yokokaya, F.; Kuhen, K.; Thayalan, P.; Chua, A.; Ng, S. H.; Cyrille, K.; Wong, J.; Sherman, D.; Pethe, K.; Glynne, R.; Beer, D.; Walker, J. R.; Smith, P.; Jiricek, J. High throughput identification of a novel lethal anti-tubercular Tetrahydropyrazolopyrimidine Carboxamide and its mechanisms of inhibition and resistance. European Molecular Biology Organization (EMBO), manuscript in preparation.